ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2170

Human Tolerogenic Dendritic Cells Generated with Protein Kinase C Inhibitor Are Optimal for Regulatory T Cell Induction-a Comparative Study

Endy Adnan1, Hitoshi Hasegawa2, Takuya Matsumoto1, Jun Ishizaki1, Sachiko Onishi1, Koichiro Suemori1 and Masaki Yasukawa1, 1Department of Hematology, Clinical Immunology, and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan, 2Department of Hematology, Clinical Immunology and Infectious Diseases, Ehime University Graduate School of Medicine, Toon, Japan

Meeting: 2014 ACR/ARHP Annual Meeting

Keywords: Dendritic cells, regulatory cells and tolerance

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print
Session Information

Title: Innate Immunity and Rheumatic Disease: Mediators, Cells and Receptors

Session Type: Abstract Submissions (ACR)

Background/Purpose

Tolerogenic dendritic cells (tDCs) are a promising tool for autoimmune diseases, transplantation and allergy. Actually, tDCs have been tried for the therapy of rheumatoid arthritis and type 1 diabetes. To date, immunomodulatory DCs are prepared from monocytes for in vitro experiments by using various agents. Previously, we generated stable tDCs with protein kinase C inhibitor (PKCI) in human and mouse and PKCI-tDCs prevented graft-versus-host disease in a murine model (J Immunol 191: 2247, 2013). The following functional characteristics are required for clinically applicable tDCs: efficient induction of functional regulatory T cells (Treg); CCR7-dependent migration; and stability under proinflammatory conditions. In this study, to select the optimal agent for clinically applicable tDCs, we compared the clinical-grade tDCs generated with various agents.

Methods

We compared tDCs generated with the following agents; vitamin D3 (Vit D3), dexamethasone (Dexa), bisindolylmaleimide I (PKCI), PPAR gamma plus retinoic acid (PPAR+RA), rapamicin (Rapa), IL-10, and TGF-beta. tDCs were prepared by adding these agents prior to the induction of maturation using TNF-alpha, IL-1beta and PGE2. We evaluated the effects of each agent on phenotype, CCR7-dependent migration, cytokine production, phagocytosis, stability, T-cell suppression, and induction of IL-10-producing T cells and functional Foxp3+ Treg cells.

Results

All tDCs except Rapa-tDCs showed an immature or semi-mature phenotype, whereas the phenotype of Rapa-tDCs resembled that of mature DCs. PKCI-tDCs, TGF-tDCs and Rapa-tDCs had moderate and high CCR7 expression, whereas tDCs generated with PPAR+RA, Vit D3, Dexa or IL-10 had very low CCR7 expression. IL-10 production by IL-10-tDCs and PKCI-tDCs was high. Immature DCs (iDCs) and PKCI-tDCs showed high production of TGF-beta. Functionally, iDCs, PKCI-tDCs, PPAR+RA-tDCs, Vit D3-tDCs and IL-10-tDCs strongly suppressed T-cell activation, whereas Dexa-tDCs, TGF-tDCs and Rapa-tDCs weakly suppressed. All tDCs showed phagocytic ability and stable tolerogenic properties under proinflammatory conditions. From these findings, PKCI-tDCs showed moderate expression of CCR7, leading to migrate toward CCR7 ligands, maintained stability, and strongly suppressed T-cell activation by generating IL-10-producing T cells and functional Foxp3+ Treg cells.

Conclusion

PKCI-tDCs appear to be optimal for clinically applicable tDCs. We expect that PKCI-tDCs are useful for tolerance-inducing therapies.


Disclosure:

E. Adnan,
None;

H. Hasegawa,
None;

T. Matsumoto,
None;

J. Ishizaki,
None;

S. Onishi,
None;

K. Suemori,
None;

M. Yasukawa,
None.

  • Tweet
  • Click to email a link to a friend (Opens in new window) Email
  • Click to print (Opens in new window) Print

« Back to 2014 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/human-tolerogenic-dendritic-cells-generated-with-protein-kinase-c-inhibitor-are-optimal-for-regulatory-t-cell-induction-a-comparative-study/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology